Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate

Immatics N.V. (NASDAQ:IMTX) is among the best German stocks to buy according to analysts. On March 5, Immatics N.V. (NASDAQ:IMTX) reported its financial results for the year ended December 31. It also provided updates on its business.

On the financial part, the company reported revenue of $56.8 million, compared to revenue of $183.1 million in 2024. For the revenue change, the management explained that in 2024, there was a one-time non-cash revenue tied to the company’s deal with Bristol Myers Squibb.

Turning to the bottom line, the company posted a net loss of $230.8 million in 2025, which compared with a net profit of $17.9 million in 2024. The management said the loss was caused by lower non-cash revenue and higher costs associated with advancement of clinical programs.

On business update, Immatics N.V. said Phase 3 SUPRAME trial for its compound called anzu-cel (IMA203) was ongoing, and that the enrollment rate was strong. This trial is on the efficacy, safety, and tolerability of this drug candidate. The anzu-cel therapy is aimed at patients with certain types of melanoma. Immatics expects to begin final analyses of the study data later in 2026. It hopes to seek marketing approval for the drug candidate in the first half of 2027, and then launch the product on the market in the second half of 2027. The company has several other drug candidates in various stages.

Immatics N.V. finished the quarter with $551.4 million in cash and other financial assets.

Immatics N.V. (NASDAQ:IMTX) is a German clinical-stage biopharmaceutical company. It’s focused on developing treatments for cancer patients. Its lead drug candidate, Anzu-cel (IMA203), targets certain types of melanoma.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. Follow Insider Monkey on Google News.